loader
Please Wait
Applying Filters...
menu
    • menu

    Information, Expiry & Status of Health Canada Patents covering Osimertinib Mesylate.

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Osimertinib Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,147Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2AstraZeneca Canada Inc.

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    Left Arrow
    Right Arrow
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    AstraZeneca Canada Inc.

    Osimertinib Mesylate
    arrow
    Luxepack
    Not Confirmed

    AstraZeneca Canada Inc.

    United Kingdom
    arrow
    Luxepack
    Not Confirmed

    Patent Expiration Date : 2032-07-25

    Date Granted : 2015-06-16

    Osimertinib Mesylate

    Brand Name : TAGRISSO

    Patent Number : 2843109

    Filing Date : 2012-07-25

    Strength per Unit : 40mg

    Dosage Form : TABLET

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2032-07-25

    Date Granted : 2015-06-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    AstraZeneca Canada Inc.

    Osimertinib Mesylate
    arrow
    Luxepack
    Not Confirmed

    AstraZeneca Canada Inc.

    United Kingdom
    arrow
    Luxepack
    Not Confirmed

    Patent Expiration Date : 2032-07-25

    Date Granted : 2015-06-16

    Osimertinib Mesylate

    Brand Name : TAGRISSO

    Patent Number : 2843109

    Filing Date : 2012-07-25

    Strength per Unit : 80mg

    Dosage Form : TABLET

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2032-07-25

    Date Granted : 2015-06-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF